Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
Full metadata record
|dc.identifier.citation||Journal of Autism and Developmental Disorders, 2019; 49(1):227-235||en|
|dc.description.abstract||Based on data from the Longitudinal Study of Australian Children linked with pharmacy dispensing data from the Australian Government's Pharmaceutical Benefits Scheme, we calculated the 1-year prevalence of psychotropic medicine supply in children and adolescents with Autism Spectrum Disorder (ASD) as reported by parents in 2014. The majority of children and adolescents with ASD in Australia were not treated with psychotropic medicine. One-third had claims for at least one psychotropic medication, most commonly medications for attention-deficit/hyperactivity disorder (ADHD), and antidepressants. Antipsychotics were supplied to less than one in twenty children and approximately one in ten adolescents. In line with findings from North America, psychotropic medicine was more often supplied to children and adolescents with ASD and comorbid ADHD.||en|
|dc.description.statementofresponsibility||Lotte Rasmussen, Nicole Pratt, Elizabeth Roughead, Anna Moffat||en|
|dc.rights||© Springer Science+Business Media, LLC, part of Springer Nature 2018||en|
|dc.subject||Autism spectrum disorder; autism; drug utilization; psychotropic drugs; Australia||en|
|dc.title||Prevalence of psychotropic medicine use in Australian children with autism spectrum disorder: a drug utilization study based on children enrolled in the longitudinal study of Australian children||en|
|dc.identifier.orcid||Pratt, N. [0000-0001-8730-8910]||en|
|Appears in Collections:||Psychology publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.